• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

National Institute for Health and Care Excellence (NICE) - Articles and news items

pembrolizumab

Price drop and new data means NICE recommends lung cancer drug pembrolizumab

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits…

NICE recommends first-in-class severe asthma treatment

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma…

Price drop means leukaemia CDF drug will be routinely available

Industry news / 2 December 2016 / Niamh Louise Marriott, Digital Editor

Ibrutinib had only previously been available through the CDF. Following a reduction in its price for the NHS, it is now recommended in further guidance…

NICE recommends faecal immunochemical tests for colorectal cancer

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

FITs are considered to be accurate because unlike other tests, they use immunochemical detection methods that are specific to human haemoglobin…

Price discount helps give green light for Roche’s breast cancer drug

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

A discount to the price of pertuzumab agreed with the company was an important factor in enabling NICE to overturn its earlier provisional decision…

NICE approves three quarters of CDF drugs for routine NHS use

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been reappraised by the National Institute for Health and Care Excellence (NICE) have received positive recommendations for routine use in the NHS. NICE has been reappraising cancer drugs which had not been recommended in previous NICE guidance (11 drug indications in total), […]

Coeliac UK ‘welcomes’ NICE’s coeliac guidance – but is it too little, too late?

Blog, Z Homepage promo / 14 November 2016 / Norma McGough, Director of Policy, Research & Campaigns, Coeliac UK

Coeliac UK’s Director of Policy, Research & Campaigns, Norma McGough, welcomes NICE’s new quality standards on coeliac disease, which she believes will bring clarity and improvement to diagnosis screening and better access to long term treatment…

UPDATE: The Cancer Drugs Fund

Blog, Industry news / 10 November 2016 / Niamh Louise Marriott, Digital Content Producer

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).  Originally introduced in 2011, The Cancer Drugs Fund (CDF) was established by the coalition Government in order to provide a means by which NHS patients in England could get cancer […]

NICE draft guidance recommends treatments for breast and lung cancer

Industry news / 10 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE recommends 2 cancer drugs for routine use on the NHS as part of its programme to appraise treatments that were available on the Cancer Drugs Fund…

NICE says head and neck cancer drug cetuximab is not cost-effective

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund…

Life-extending breast cancer drug approved by NICE

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE has said eribulin, which is also called Halaven and made by Eisai, should be an option for people with locally advanced or metastatic breast cancer…

NICE recommends ‘breakthrough’ drug nivolumab for advanced renal cell cancer

Industry news / 21 October 2016 / Niamh Louise Marriott, Digital Content Producer

Nivolumab is an intravenous drug, a form of immunotherapy that works by harnessing the power of the patient’s own immune system to destroy the cancer cells…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +